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Background: Neurosurgical procedures such as craniotomy and brain tumor resection could potentially lead to
unavoidable cerebral injuries. Matrix metalloproteinase-9 (MMP-9) is up-regulated in neurological injuries. Statins
have been suggested to reduce MMP- 9 level and lead to neuroprotection. Atorvastatin preoperatively administered
to evaluate its neuroprotective effects and outcome assessment in neurosurgical-induced brain injuries after glial
tumor resection. In this prospective, randomized, double-blind, placebo-controlled trial, 42 patients undergoing glial
tumor surgery randomly received 40 mg atorvastatin or placebo twice daily from seven days prior to operation and
continued for a 3 weeks period. Plasma MMP-9 concentration measured 4 times, immediately before starting atorvastatin
or placebo, immediately before surgery, 24 hours and two weeks after the surgery. Karnofsky performance score was
assessed before first dose of atorvastatin as a baseline and 2 months after the surgery.
Results: Karnofsky performance scale after surgery raised significantly more in Atorvastatin group (11.43 +/− 10.62 vs.
4.00 +/− 8.21) (p = 0.03). Atorvastatin did not significantly reduce MMP-9 plasma concentration 24 hours after
surgery in comparison to placebo. No statistical significance detected regarding length of hospital stay among the
groups. Significant reduction in MMP-9 plasma concentration was recorded in atorvastatin group two weeks after
surgery (p = 0.048).
Conclusions: Significant statistical differences detected with atorvastatin group regarding MMP-9 plasma concentration,
clinical outcome and Karnofsky performance score. Consequently, atorvastatin use may lead to better outcome after
neurosurgical procedures.
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Neurosurgical procedures could be complicated by a diverse
spectrum of factors, such as direct trauma, hemorrhage,
brain retraction, and electrocautery with subsequent mor-
bidity and mortality. Blood–brain barrier (BBB) disruption
and brain edema is one of the proposed causalities [1,2].
Discovering novel neuro-protective agents and suggesting
pre-operative regimen can result in better outcome after* Correspondence: khgholami@tums.ac.ir
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reproduction in any medium, provided the orbrain surgeries. The matrix metalloproteinases (MMPs)
are enzymes that play important roles in physiologic
and pathophysiologic processes. These enzymes’ levels
mostly are not detectable, and increase in response to
transcriptional regulators [3,4]. MMP-9 (Gelatinase B) is
up-regulated in neurological injuries such as cerebral ische-
mia, BBB disruption, edema formation, and hemorrhagic
transformation [5-8]. Different explanations provided to
clarify relation of this enzyme and neurotoxicity [9-11].
In particular MMP-9 level rises in acute neurological in-
juries, so this enzyme proposed to be closely related to
neurological impairments [3,12,13]. On the other hand,al Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tective, and appropriate for the treatment of acute brain
injuries [14-16]. Experimental studies suggest that pre-
operative inhibition of MMP-9 reduce brain injuries
following neurosurgical procedures [1,2].
Statins not only lower cholesterol effectively [17] but
also have other properties called “pleiotropic effects.”
Several clinical trials have indicated that statins suppress
inflammatory reactions, recover neurological injuries,
decrease the incidence of ischemic stroke, improve endothe-
lial function, inhibit platelet activation, control vasospasm
following subarachnoid hemorrhage, have neuroprotective
activity in spinal cord injury, and prevent progression
of Alzheimer’s disease [18-30]. There are published docu-
ments claiming that statins decrease MMP-9 levels [30-32].
Many of these evidences are related to atorvastatin, a
potent member of this family. This study was designed
to evaluate atorvastatin effects on plasma MMP-9 concen-
tration in neurosurgical- induced brain injuries after glial
tumor resection. To minimize confounding factors Patients
with gliomas grade 1, 2 and 3 which pathologically do
not increase MMP-9 plasma levels substantially were
entered the study and patients with Glioblastomamultiforme
(GBM) were excluded.Methods
This is a randomized, double blind, placebo-controlled
prospective clinical trial performed in neurosurgery
ward of a tertiary care Hospital from March 2011 to
December 2012. The protocol was approved by the eth-
ics committee of Tehran University of Medical Sciences
(TUMS). This clinical trial was registered at Iranian
Registry of Clinical Trial (IRCT) with the registration
ID of “IRCT201203039196N1”. For detecting any signifi-
cant changes of MMP-9 concentration as main endpoint a
sample size was calculated to be 21 patients at each group.
Standard deviation for plasma MMP9 in human was
supposed 23 ng/ml and 20 ng/ml was accepted as sig-
nificant rise in MMP9 level, with α = 0.05 and ß = 0.20.
[n = 2(Z1- α/2+ Z1-β)2 S2/d2, i.e. n = 2(1.96 + 0.84)2 ×
232/202, n = 21] Patients undergoing elective surgery
as therapeutic approach for tumor resection with diagno-
sis of glial tumor based on radiographic findings were
included in this study. Patients excluded from the study
with any atorvastatin contraindications such as, atorvastatin
sensitivity, active hepatic disease, pregnancy and lactation;
elevated liver enzymes; history of serious adverse reaction
induced by atorvastatin; severe renal or hepatic failure;
concurrent infectious disease; use of atorvastatin or other
statins before the study; pathology report of other type
of tumors instead of glioma grade 1,2 and 3; serious
interaction between patients medications and atorvastatin;
MAP < 70 mmHg; Na < 130 mEq/L; Hematocrit < 28%.After obtaining informed consent, using permuted-block
randomization patients were randomly assigned to atorva-
statin or placebo group. Patients received atorvastatin or
placebo 40 mg oral tablets, twice daily (totally 80 mg) for
3 weeks, from one week before to 2 weeks after surgery.
Standard therapeutic regimen and supportive care, such
as antibiotic prophylaxis, seizure prophylaxis, fluid ther-
apy, and gastro intestinal ulcer prophylaxis have been used
for both groups. This standard therapeutic regimen was
including cefazolin as antibiotic prophylaxis, phenytoin for
seizure prophylaxis, appropriate fluid therapy with normal
saline, ranitidine as gastrointestinal ulcer prophylaxis, and
dexamethasone for controlling brain edema after surgery.
At the beginning of the study, patients’ demographic data
such as age, sex, weight, comorbidity (having any concur-
rent disease other than glial tumor), history of hyperten-
sion, drug history, and neurological exam were collected
on pre-designed questionnaires. Laboratory data recorded
at baseline, were as follow: Fasting blood sugar (FBS),
creatinin (Cr), blood urea nitrogen (BUN), white blood
cell count (WBC count), hemoglobin, erythrocyte sedi-
mentation rate (ESR), C-reactive protein (CRP), liver
function tests (LFTs), lipid profile (including total choles-
terol, LDL Cholesterol, HDL Cholesterol, and triglycerides).
For detection of plasma MMP-9 concentration blood
samples collected 4 times from each patient: immediately
before starting atorvastatin or placebo, immediately before
surgery, 24 hours and two weeks after the surgery. The
plasma MMP-9 measured by enzyme-linked immuno-
sorbent assay (ELISA) kits, Quantikine®, manufactured by
R&D Systems, United States of America. Based on the kit
catalog recommendations blood samples carried with
heparinized tubes on ice. To separate plasma, blood
centrifuged for 15 minutes at 1000 × g within 30 mi-
nutes of collection. Following the above an additional
centrifugation step of the plasma at 10,000 × g for
10 minutes at 2 - 8°C performed for complete platelet
removal, then all samples stored at −80°C till the assay
day. This kit uses the quantitative sandwich enzyme
immunoassay technique to assay MMP-9 levels. A mono-
clonal antibody specific for MMP-9 has been pre-coated
on a microplate. All Standard samples and study samples
are pipetted into the wells, and MMP-9 is bound by the
immobilized antibody. Following washing away unbound
substances, an enzyme-linked polyclonal antibody specific
for MMP-9 is added to the wells. After a wash to eliminate
unbound antibody-enzyme reagent, a substrate solution is
added to the wells and color develops in proportion to the
quantity of MMP-9 bound in the primary step. The color
expansion is stopped and the intensity of the color is
measured.
Clinical outcome were assessed with Karnofsky perform-
ance score at the baseline (one week before surgery) and
2 months after the surgery by the same examiner. Type
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Hospital stay defined as number of nights patient spent
at the hospital. Our patients were closely observed for
atorvastatin adverse effects, by interviewing patients
during hospitalization and also after discharge in the
clinic. Baseline and LFTs was measured in all patients
and recheck CPK in any patient with symptoms suggestive
of myopathy and also repeat transaminase levels when
clinically indicated thereafter was about to be done. High
rate reported adverse reactions such as diarrhea, arthralgia,
limb pain, myalgia, muscle spasms, musculoskeletal pain,
insomnia, nausea, and dyspepsia was asked from each
patient specifically.
Statistical analyses were executed with the Statistical
Package for Social Sciences (SPSS version 17; SPSS Inc.,
Chicago, IL, USA) and significance level was defined as
p-value less than 0.05. The normal distribution of quan-
titative data was assessed with one sample Kolmogorov-
Smirnov test. Data with a normal distribution were
expressed as means ± standard deviations (SDs) and stu-
dent t-test as well as paired t-test was used to compare
quantitative variables between or within groups, re-
spectively. The Mann–Whitney U test and Wilcoxon
test were applied to compare non-normally distributed
data (expressed as median (inter quartile range) to assess
differences between and within groups, respectively.
Regarding qualitative variables (categorical data), the chi-
square or Fisher's exact test were performed.Results
Forty- two patients, (25 males and 17 females) randomly
assigned to 21 in atorvastatin group and 21 in placebo
group. Patients’ demographic data is presented in Table 1.
Patients mean ± SD age were 53.62 ± 15 years for ator-
vastatin group, and 40.43 ± 13.09 years in placebo group
(p = 0.006, 95% CI: - 22.31- -4.08).
There were no statistically significant difference in regard
to baseline parameters such as sex, weight, comorbidity (11
patients with hypertension [26%], 5 patients with ischemic
heart disease [12%], 2 patients with gastrointestinal diseases
[4.7%], one with lumbar herniated disc [2.4%], a patient
with inherited neurofibromyalgia[2.4%], a patient with
cataract [2.4%], and one patient with glaucoma [2.4%]),
hypertension, concurrent drug therapy, and laboratory
data such as FBS, Cr, BUN, WBC count, ESR, CRP
(Table 1). The drug history of each patient obtained care-
fully, and there was no significant difference among the
groups regarding medications. Considering drugs that may
affect level of MMP-9 just 6 (3 patients in atorvastatin and
3 in placebo group) patients took low doses of aspirin
(81 mg) to suppress platelet function. Dexamethasone as a
part of standard post-operative protocol administered to
all of the patients, 8 mg three times daily.There were significant differences between baseline lipid
profile (total cholesterol (p = 0.006), LDL Cholesterol (p =
0.009), and triglycerides (p = 0.04)) of the study groups.
Lipid levels were higher in atorvastatin group; however, in
both groups patients were not categorized as hyperlipid-
emic (Table 1).
Baseline plasma MMP-9 concentration, Karnofsky per-
formance score, type of tumor, and grade of tumor among
the groups were not significantly different (Table 1).
Pathologic reports indicated grade 1, 2, 3 of glial tumor
including, ependymoma grade 1 and 2, pilomyxoid as-
trocytoma, grade 2 astrocytoma, oligodendroglioma,
ganglioglioma, anaplastic astrocytoma, and anaplastic
oligodendroglioma.
Comparison of Karnofsky performance scale before and
2 months after surgery showed no significant difference
among the groups (p = 0.07), however by further explor-
ation of patients leading to exclusion of just one patient as
outlier, significant difference showed up (p = 0.03). Atorva-
statin group showed significantly better improvement of
Karnofsky performance scale after surgery (11.43 ± 10.62 vs.
4.00 ± 8.21).
MMP-9 plasma level changes, immediately before surgery
and 24 hours after surgery was not significantly different
among the groups (p = 0.38).
In within group statistical analysis Karnofsky perform-
ance score showed significant increase in both atorvastatin
(P = 0.001) and placebo (P = 0.03) groups. However, as it is
depicted in Table 2 more progression was seen in atorva-
statin group. MMP-9 plasma concentration levels increased
significantly 24 hours after surgery in placebo group (P =
0.02). Nevertheless, there was no significant rise in MMP-9
levels in the atorvastatin group (P = 0.42). Comparison of
MMP-9 plasma levels before surgery and 2 weeks after
surgery revealed no significant changes in any of the
groups, however there were an increasing trend in the
placebo group and a decreasing trend in the atorvastatin
group (Table 2).
Comparison of MMP −9 plasma level changes just
before surgery with 2 weeks after surgery demonstrated
significant difference among the groups (p = 0.048). In-
crease in MMP-9 levels 2 weeks after surgery was less
in atorvastatin group. Atorvastatin and placebo groups
MMP-9 plasma level changes between the first week of
drug therapy and before surgery (1st and 2nd measure-
ments), and changes between 3rd and 4th measurements in-
dicated no significant difference. Likewise, comparison of
ESR and CRP measurements before and after surgery did
not indicate any significance in response to atorvastatin
treatment.
Length of hospital stay was slightly in favor of atorva-
statin group, but not to a significant degree (8.52 ±
6.77 days for drug group, and 11.29 ± 11.50 days for pla-
cebo group). There was no significant relation between
Table 1 Distribution of the baseline demographic and medical characteristics of patients in atorvastatin and placebo groups




Age 53.62 ± 15 40.43 ± 13.09 0.006(95% CI: - 22.31- -4.08)
Weight 75.95 ± 12.35 72.43 ± 16.63 0.44(95% CI: - 12.66- 5.61)
Comorbidity 14 8 0.06
Hypertension 8 3 0.08
Concurrent drug therapy 14 8 0.06
FBS 94.57 ± 17.72 94.43 ± 24.16 0.98(95% CI: -13.36 – 13.07)
Cr 0.93 ± 0.19 0.81 ± 0.15 0.03 (95% CI: -0.23 – -0.01)
BUN 19.90 ± 6.36 15.48 ± 5.44 0.02(95% CI: -8.12 – -074)
WBC count 7400.48 ± 2857.89 7968.57 ± 379.129 0.98
ESR 20.24 ± 8.54 23.00 ± 10.29 0.35(95% CI: -3.13 – 8.66)
CRP 10.52 ± 10.96 11.62 ± 10.28 0.50
Total cholesterol 198.86 ± 33.45 173.52 ± 31.88 0.006
LDL cholesterol 129.62 ± 30.69 107.76 ± 31.73 0.009
Triglycerides 153.14 ± 50.58 173.52 ± 31.88 0.04
Plasma MMP-9 concentration 256.24 ± 279.81 130.95 ± 78.50 0.33
Karnofsky performance scale 82.38 ± 17.29 76.67 ± 19.32 0.25
Grade of tumor 0.80
Grade 1 4 3
Grade 2 15 15
Grade 3 2 3
Type of tumor 0.73
Ependymoma grade 1 0 1
Ependymoma grade 2 4 2
Pilomyxoid astrocytoma 0 2
Astrocytoma grade 2 5 7
Oligodendroglioma 3 4
Ganglioglioma 3 0
Anaplastic astrocytoma 2 1
Anaplastic oligodendroglioma 0 2
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changes, or hospital stay in any of the groups. BUN
and Cr level changes were not significantly different be-
tween two groups. No adverse drug reaction reported by








Drug group 190.14 ± 197.74 236.38 ±225.08
Placebo group 130.19 ± 83.04 184.81 ± 107.04Discussion
Neurosurgical procedures can induce serious neurological
injuries [1,2]. Different medications such as diuretics,
osmotic agents, and corticosteroids are suggested to













164.95 ± 126.68 82.38 ± 17.29 93.81 ± 9.73
180.81 ± 115.93 76.67 ± 19.32 82.86 ± 14.88
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histochemical evidences specified that MMP-9 increases
surrounding surgical induced brain injury areas [2]. Two
experimental studies have demonstrated that MMP inhibi-
tors preserve the BBB, attenuate brain edema, and act as a
neuroprotectant after brain surgery [1,2].
There is some evidence that suggesting statins decrease
MMP-9 levels [30-32]. Various retrospective and prospect-
ive clinical trials, meta-analysis, and researches evaluated
pleiotropic effects of statins on surgical outcome. In
cardiac, vascular, or non cardiovascular operations, ir-
respective to the type of surgery, positive effects and
reduction of undesirable postoperative outcomes, such
as mortality, morbidity, length of hospital and ICU stay
have been reported fallowing statin therapy [34-38].
Neuro-protective effects of statins were established in
many studies [19-30].
In this prospective, randomized, double blind, controlled
trial, 42 patients underwent glial tumor surgery, atorva-
statin 40 mg or placebo used two times daily. Since most
of the studies use full dose of statins to evaluate surgical
induced injuries, 80 mg atorvastatin as a full dose is used
in this study. Results demonstrated significant reduction
in MMP-9 plasma level in atorvastatin patients after two
weeks. Regarding clinical endpoint (Karnofsky performance
scale at 2 months after surgery), better outcome observed
in atorvastatin group. Length of hospital stay was less in pa-
tients who had received atorvastatin, but not to a statistical
significant degree.
Plasma MMP9 changes followed the anticipated pattern.
No significant change observed in the baseline measure-
ment and second measurement (immediately before sur-
gery), since there was no neuronal injury happened before
surgery. Plasma MMP9 increased 24 hours after surgery
as expected confirming the hypothesis of MMP9 surge
after surgery. There was decrease in the MMP9 plasma
concentration 2 weeks after surgery indicating improve-
ment in patients. Between groups, statistical analyses dem-
onstrated that atorvastatin group had significantly more
reduction in MMP9 level after two weeks in comparison
with placebo.
Within group statistical analyses revealed that atorva-
statin diminished MMP-9 peak 24 hours after surgery. This
outcome improvement was also confirmed by better neuro-
logical outcome as assessed with Karnofsky performance
score in atorvastatin group. Despite no significant change
in MMP-9 plasma concentration 2 weeks after surgery in
within group statistical analyses, mean level increased in
placebo group and decreased in atorvastatin group. All
these findings indicate beneficial effects of atorvastatin in
these patients.
Anti-inflammatory effects and MMP9 suppression appear
to be irrelevant to concomitant medications. Although age
of two patient groups was significantly different, there wasno significant relation between age and outcome variables
(i.e. karnofsky performance score, MMP9 level changes,
or hospital stay).
Atorvastatin administration was well tolerated during
the study period. No adverse drug reaction detected
same as other studies on statins [37,38]. Acute kidney
injuries were recently reported with high doses of statins
[39-42]; therefore renal laboratory values were carefully
monitored in this study. There were no significant changes
in renal laboratory values between two groups. There is
even a retrospective cohort of 98,939 patients who under-
went various operations including; major open abdominal,
cardiac, thoracic, or vascular procedure between 2000 and
2010 claims that statin use before surgery reduce risk of
postoperative acute kidney injury [42]. Preoperative statin
therapy decreased the need for postoperative renal replace-
ment therapy [34].
Study had some limitations due to complexity of neuro-
logic, physiologic and pathologic of human brain. Due to
diversity of functioning regions of brain each glioma can
cause different symptoms and debilities in different func-
tioning parts of human brain within and or between dif-
ferent groups of patients pre and postoperatively. Due to
complexity of circuits of brain (mostly unknown) different
people suffer from different disabilities even when the
glioma is operated on, in same area of brain; different
surgical approaches caused different complications that
could have been misinterpreted as effect of drug while
being merely surgical.
Conclusion
Pre-operative atorvastatin administration resulted in re-
duction of MMP-9 level 2 weeks postoperatively and
improvement of Karnofsky performance scale 2 month
after surgery. Larger trials, longer duration of statin ther-
apy, retrospective analysis of neurosurgical procedures in
patients with long term statins use, could be helpful for
decisive evidence.
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